With the Anglonordic Life Science Conference last week, BioEquity next week, ASGCT Annual meeting and LSX Nordic Congress around the corner, it is a good time to practice your pitching. Funds are open and now is the time to foster those new and old connections. Read on to discover what has happened this week and […]
A profoundly positive response from Anglonordic attendees with hands shaken, conversations started and potential deals in the works. The main takeaway was the benefit of it being a ‘boutique’ event, meaning everyone could make the most of the 1:1 partnering, pitch presentations, and networking breaks. Keep reading to hear more about what’s been happening this […]
Drum roll… In Vivo’s 2026 Rising Leaders were announced this week and included not one, not two, but five Optimum clients. A huge congratulations to Colleen Acosta of Freya Biosciences, Diana Čekatauskaitė of Lonza’s Synaffix, Reuben Dawkins of Link Biologics, Michelle Morrow of Nucleome Therapeutics, and Javier Nunez-Vicandi of Sofinnova Partners. This list recognises not […]
Highly experienced biopharma executive Dr Cristina Csimma joins Asgard’s Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof Brian Brown join Advisory Board Appointments strengthen Asgard’s team as it progresses IND-enabling studies for its lead asset AT-108 – a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses […]
Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalities AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses Lund, Sweden, […]
